Journal of the American Academy of Dermatology
Volume 62, Issue 3 , Pages 427-436 , March 2010

A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti–interferon-alfa monoclonal antibody, in subjects with chronic psoriasis

  • Robert Bissonnette, MD

      Affiliations

    • Innovaderm Research, Inc, Montreal, Quebec, Canada
    • ,
  • Kim Papp, MD

      Affiliations

    • Probity Medical Research, Waterloo, Ontario, Canada
    • ,
  • Catherine Maari, MD

      Affiliations

    • Innovaderm Research, Inc, Laval, Quebec, Canada
    • ,
  • Yihong Yao, PhD

      Affiliations

    • MedImmune, LLC, Gaithersburg, Maryland
    • ,
  • Gabriel Robbie, PhD

      Affiliations

    • MedImmune, LLC, Gaithersburg, Maryland
    • ,
  • Wendy I. White, PhD

      Affiliations

    • MedImmune, LLC, Gaithersburg, Maryland
    • ,
  • Chenxiong Le, PhD

      Affiliations

    • MedImmune, LLC, Gaithersburg, Maryland
    • ,
  • Barbara White, MD

      Affiliations

    • MedImmune, LLC, Gaithersburg, Maryland
    • Corresponding Author InformationReprint requests: Barbara White, MD, MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878.

,Accepted 14 May 2009.

References 

  1. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?. J Am Acad Dermatol. 2000;43:281–285
  2. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280–284
  3. Valdimarrsson H, Baker BS, Jonsdottir I, Fry L. Psoriasis: a disease of abnormal keratinocytes proliferation induced by T lymphocytes. Immunol Today. 1986;7:256–259
  4. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1:442–447
  5. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–390
  6. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842–1847
  7. Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol. 2002;71:565–581
  8. Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferon-alpha. Br J Dermatol. 1991;125:463–465
  9. Pauluzzi P, Kokelj F, Perkan V, Pozzato G, Moretti M. Psoriasis exacerbation induced by interferon-alpha. Report of two cases. Acta Derm Venereol. 1993;73:395
  10. Ketikoglou I, Karatapanis S, Elefsiniotis I, Kafiri G, Moulakakis A. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol. 2005;15:107–109
  11. Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, Burg G, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004;140:1490–1495
  12. van der Fits L, van der Wel LI, Laman JD, Prens EP, Verschuren MC. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol. 2004;122:51–60
  13. Schmid P, Itin P, Cox D, McMaster GK, Horisberger MA. The type I interferon system is locally activated in psoriatic lesions. J Interferon Res. 1994;14:229–234
  14. Fah J, Pavlovic J, Burg G. Expression of MxA protein in inflammatory dermatoses. J Histochem Cytochem. 1995;43:47–52
  15. Suomela S, Cao L, Bowcock A, Saarialho-Kere U. Interferon alpha-inducible protein 27 (IFI27) is upregulated in psoriatic skin and certain epithelial cancers. J Invest Dermatol. 2004;122:717–721
  16. Yao Y, Richman L, Morehouse C, de los Reyes M, Higgs BW, Boutrin A, et al. Type I interferon: Potential therapeutic target for psoriasis?. PLoS ONE. 2008;3:e2737
  17. Eriksen KW, Lovato P, Skov L, Krejsgaard T, Kaltoft K, Geisler C, et al. Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol. 2005;125:936–944
  18. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202:135–143
  19. Hida S, Ogasawara K, Sato K, Abe M, Takayanagi H, Yokochi T, et al. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity. 2000;13:643–655
  20. Yao Y, Higgs BW, Morehouse C, de los Reyes M, Trigona W, Brohawn P, et al. Development of potential pharmacodynamic and diagnostic markers for anti–IFN-α monoclonal antibody trials in systemic lupus erythematosus. Human Genomics and Proteomics. 2009;Article ID 374312, 16 pages. doi:10.4061/2009/374312
  21. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13:59–68
  22. Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007;56:3784–3792
  23. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis. 2007;66:1008–1014
  24. Coelho LF, de Oliveira JG, Kroon EG. Interferons and scleroderma—a new clue to understanding the pathogenesis of scleroderma?. Immunol Lett. 2008;118:110–115
  25. Wallace D, Petri M, Olsen N, Kirou K, Dennis G, Yao Y, et al. MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus (abstract). Arthritis Rheum. 2007;56(suppl 9):S526–S527Abstract 1315
  26. Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216
  27. Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157:238–244
  28. Ortonne JP, Shear N, Shumack S, Henninger E CLEAR Multinational Study Group. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol. 2005;5:13
  29. Dillman RO, Hendrix CS. Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Support Cancer Ther. 2003;1:38–48
  30. LaFleur DW, Nardelli B, Tsareva T, Mather D, Feng P, Semenuk M, et al. Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem. 2001;276:39765–39771

 Supported by MedImmune, LLC.

 Disclosure: Drs Yao, Robbie, White, Le, and White are employees of MedImmune. Dr Bissonnette received research funding from MedImmune for this study; has received research funding, is a consultant, and/or has received honoraria from MedImmune, LLC, Amgen, Inc, Wyeth, Inc, Centocor/Schering-Plough, Ortho-Biotech, Abbott Laboratories, Astellas, and EMD Serono, Inc. Dr Papp received research funding from MedImmune for this study; has received research funding, is a consultant, Speaker Bureau, and/or investigator for MedImmune, Abbott Laboratories, Amgen, Inc, Celgene Corporation, Merck-Serono, Schering-Plough, and Wyeth, Inc. Dr Maari received research funding from MedImmune for this study; is a consultant and/or has received honoraria from Amgen, Inc, Wyeth, Inc, Centocor/Schering-Plough, Ortho-Biotech, Abbott Laboratories, Astellas, and Galderma.

PII: S0190-9622(09)00686-0

doi: 10.1016/j.jaad.2009.05.042

Journal of the American Academy of Dermatology
Volume 62, Issue 3 , Pages 427-436 , March 2010

Article Tools

* Image Usage & Resolution